Publications by authors named "Katherine C Pehlivan"
High grade gliomas are identified as malignant central nervous tumors that spread rapidly and have a universally poor prognosis. Historically high grade gliomas in the pediatric population have been treated similarly to adult high grade gliomas. For the first time, the most recent classification of central nervous system tumors by World Health Organization has divided adult from pediatric type diffuse high grade gliomas, underscoring the biologic differences between these tumors in different age groups.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the use of magnetic resonance-guided stereotactic laser ablation (SLA) for treating pediatric brain tumors at a single institution over a four-year period.
- A total of 18 ablation procedures were performed on 17 patients, with a focus on various tumor types and evaluation of outcomes; most patients saw a significant reduction in tumor size post-procedure.
- The results indicate SLA is a promising minimally invasive treatment for pediatric low-grade brain tumors, showing particularly positive responses, but some complications were noted, including a 29% complication rate.
Trametinib-based Treatment of Pediatric CNS Tumors: A Single Institutional Experience.
J Pediatr Hematol Oncol
November 2020
MEK inhibitors are an emerging therapy with increasing use in mitogen-activated protein kinase-driven central nervous system (CNS) tumors. There is limited data regarding efficacy and toxicity in pediatric patients. We report our clinical experience with trametinib-based therapy for the treatment of 14 consecutive pediatric patients with recurrent low-grade glioma (N=11) or high-grade CNS tumors (N=3) with MAP kinase pathway mutations.
View Article and Find Full Text PDFPurpose Of Review: Genetically engineered T cells expressing a chimeric antigen receptor (CAR-T) targeting specific antigens present on acute lymphoblastic leukemia (ALL) blasts have generated promising results in children and adults with relapsed and refractory disease. We review the current evidence for CAR-T cell therapy in ALL, associated toxicities, and efforts to improve durable response to therapy.
Recent Findings: CD19-directed CAR-T cells have recently been approved by the FDA for use in children and young adults with ALL and in adults with diffuse large B cell lymphoma (DLBCL) in the relapsed/refractory setting.